Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2023-05-25 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于持股5%以上股东减持达到1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement from Shanghai Medicilon Biopharmaceutical Co., Ltd. regarding the reduction of shareholdings by shareholders holding more than 5% of the company's shares. It details the shareholding changes, percentages before and after the reduction, and confirms that the controlling shareholder and actual controller remain unchanged. The document includes specific dates and quantities of shares reduced by various shareholders. This type of disclosure is typical of notifications about changes in major shareholdings, especially when crossing significant thresholds or reducing holdings by a notable percentage. There is no indication of financial statements, audit information, management discussion, or other report types. The document is not a report publication announcement or a certification letter but a direct announcement of shareholding changes. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2023-05-25 Chinese
美迪西：2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2022 Annual General Meeting (AGM) of Shanghai Medicilon Biopharmaceutical Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals including the 2022 annual report, financial statements, profit distribution, appointment of auditors, and other governance matters. The document is not the annual report itself but the official announcement of the voting results and resolutions from the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is over 5,000 characters and contains detailed voting data, confirming it is not a mere report publication announcement or a regulatory filing. Therefore, the correct classification is DVA with high confidence.
2023-05-18 Chinese
北京金诚同达（上海）律师事务所关于上海美迪西生物医药股份有限公司2022年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and procedures of the 2022 Annual General Meeting (AGM) of Shanghai Medicilon Inc. It details the convening, attendance, agenda, voting procedures, and results of the AGM. The document does not contain financial statements or management discussion but focuses on the legal compliance of the AGM process. It is not the AGM materials themselves but a legal opinion related to the AGM. Given the content and purpose, this document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it confirms the legality and results of the shareholder meeting and voting process. The document length is 4559 characters, which is sufficient for a detailed legal opinion but not a full annual report or financial report. Therefore, the classification is DVA with high confidence.
2023-05-18 Chinese
美迪西：关于股东减持股份数量过半暨减持股份进展公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from Shanghai Medicilon Biopharmaceutical Co., Ltd. regarding the progress of a shareholder share reduction plan. It details the shareholders involved, the number of shares held before and after reduction, the progress of the reduction plan, and related risk disclosures. The document is focused on reporting the progress of shareholding changes by insiders or major shareholders, including specific share quantities and percentages. It does not contain financial statements, earnings data, or management discussion of financial results. It is not a report of a general meeting, nor a proxy solicitation, nor a dividend notice. The content fits the definition of a Director's Dealing or Major Shareholding Notification. Since it involves multiple shareholders reducing their holdings and detailed shareholding percentages, it aligns best with Major Shareholding Notification (MRQ). The document length is 3667 characters, which is typical for such announcements. Therefore, the classification is MRQ with high confidence.
2023-05-18 Chinese
美迪西：关于持股5%以上股东减持达到1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a shareholder's reduction in holdings exceeding 1%, specifically detailing the shareholding changes of shareholders Lin Changqing and Chen Guoxing. It includes precise share counts, percentages before and after the reduction, and references to compliance with securities laws and disclosure obligations. The document is a formal announcement of a change in major shareholding levels, not a financial report or other type of filing. It matches the definition of a Major Shareholding Notification (MRQ). The document length is 2092 characters, which is typical for such announcements. Therefore, the correct classification is MRQ with high confidence.
2023-05-17 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司首次公开发行股票并在科创板上市之保荐总结报告书
Audit Report / Information Classification · 95% confidence The document is titled as a "保荐总结报告书" which translates to "Sponsorship Summary Report" related to the initial public offering (IPO) and listing of Shanghai Medicilon Inc. on the STAR Market. It details the sponsorship institution's responsibilities, due diligence, continuous supervision, major events during the sponsorship period, and compliance with regulatory requirements. The document is a comprehensive summary report issued by the sponsor (Guangfa Securities) after the IPO and listing process, covering the entire sponsorship period and related activities. It is not an annual report, earnings release, or a regulatory filing announcement. It is a detailed report summarizing the sponsorship work and continuous supervision, which aligns with the category of Audit Report / Information (AR) as it includes audit-like oversight, compliance checks, and verification of fundraising usage, but is not a full annual report or financial statement. Therefore, the best fitting category is AR (Audit Report / Information). The document length (5324 characters) supports it being a full report rather than a brief announcement or certification. FY 2022
2023-05-12 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.